India to Netherlands: Amlodipine Export Trade Route

To import Amlodipine formulations into the Netherlands, the following approvals and registrations are necessary:

• Marketing Authorization: A valid marketing authorization from the MEB is mandatory. The application must be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format, encompassing comprehensive data on quality, safety, and efficacy.

• Manufacturing and Importation Authorization: Entities involved in manufacturing or importing medicinal products must possess appropriate authorizations. The MEB issues these licenses, ensuring compliance with Good Manufacturing Practice (GMP) standards. (english.cbg-meb.nl)

• GMP Compliance: Manufacturers, including those in third countries like India, must comply with EU GMP standards. The Health and Youth Care Inspectorate (IGJ) conducts inspections to verify adherence. A GMP certificate is issued within 90 days post-inspection if compliance is confirmed. (english.cbg-meb.nl)

• Product Registration Fees: While specific fees may vary, applicants should anticipate costs associated with marketing authorization applications, GMP inspections, and other regulatory processes.

Indian manufacturers exporting Amlodipine formulations to the Netherlands must meet the following GMP certifications:

• EU GMP Certification: Compliance with EU GMP standards is obligatory. The IGJ inspects manufacturing sites to ensure adherence. A GMP certificate, valid for three years, is issued upon successful inspection. (english.cbg-meb.nl)

• Approved Facilities: Manufacturing sites must be listed in the EudraGMDP database, confirming their compliance status. Regular inspections are conducted to maintain this status.

• Recent Inspections and Actions: The IGJ has experienced delays in GMP inspections due to the COVID-19 pandemic, leading to backlogs. Priority has been given to facilities involved in COVID-19 vaccine production. (english.cbg-meb.nl)

Several regulatory changes have impacted Indian pharmaceutical exports to the Netherlands:

• Revised GMP Rules in India (January 2024): India's Ministry of Health updated GMP regulations to align with global standards, introducing a pharmaceutical quality system, quality risk management, and product quality review. These changes aim to enhance the quality of pharmaceutical exports.

• Resumption of Regular Inspections (2025): The IGJ resumed regular on-site GMP inspections, addressing backlogs caused by the pandemic. Manufacturers should ensure compliance to avoid potential regulatory actions. (english.cbg-meb.nl)

Staying informed about these developments is crucial for Indian exporters to maintain compliance and ensure uninterrupted access to the Dutch market.

Amlodipine, a calcium channel blocker, is widely prescribed in the Netherlands for managing hypertension and angina. The prevalence of hypertension in the Dutch adult population is approximately 30%, contributing significantly to the demand for antihypertensive medications. In 2024, the Netherlands' pharmaceutical market was valued at around $8 billion, with cardiovascular drugs accounting for approximately 15% of this total. The aging population, with over 20% aged 65 and above, further drives the demand for antihypertensive treatments. The Netherlands maintains a robust pharmaceutical manufacturing sector, producing a substantial portion of its medicinal needs domestically. However, to meet specific demands and ensure a diverse supply, the country also imports finished pharmaceutical formulations, including those containing amlodipine.

The Netherlands applies a 0% Most-Favored-Nation (MFN) import duty rate on pharmaceutical products classified under HS code 30049072, which includes finished formulations containing amlodipine. This exemption aligns with the European Union's commitment to facilitating access to essential medicines. Additionally, the Netherlands imposes a Value Added Tax (VAT) of 9% on pharmaceutical products. There are no specific Free Trade Agreements (FTAs) between India and the Netherlands that alter this tariff structure for pharmaceutical imports. Furthermore, there are no anti-dumping duties imposed on amlodipine formulations imported into the Netherlands.

India is a significant supplier of amlodipine formulations to the Netherlands, with exports valued at $25.2 million, accounting for 0.2% of India's total amlodipine formulation exports. Other major suppliers include European Union member states, which benefit from proximity and established trade relationships. India's competitive pricing, driven by cost-effective manufacturing processes and economies of scale, often positions it favorably against European manufacturers. While specific pricing data varies, Indian pharmaceutical products are generally more affordable, providing a cost-effective option for Dutch importers seeking quality medications.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. The country's pharmaceutical industry is valued at over USD 50 billion, with exports accounting for more than USD 25 billion.

The nation boasts a robust manufacturing infrastructure, with over 650 U.S. FDA-approved facilities and more than 2,000 WHO-GMP-certified plants. This extensive network enables large-scale production of finished dosage forms, including tablets and capsules containing Amlodipine.

India's cost-effective production capabilities are driven by a skilled workforce and economies of scale, allowing for competitive pricing of Amlodipine formulations without compromising quality. The country's pharmaceutical sector has experienced consistent growth, with a compound annual growth rate (CAGR) of 9.1% over the past seven years, outpacing overall GDP growth.

India's Amlodipine formulations are competitively priced compared to those from China and the European Union. The country's cost-effective production methods and large-scale manufacturing contribute to lower unit prices for finished dosage forms. In contrast, European manufacturers often have higher production costs, leading to more expensive branded generics.

In terms of quality, Indian pharmaceutical companies have made significant strides in regulatory compliance. As of 2024, India has surpassed the United States in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved facilities. Compliance has improved significantly, with US FDA Official Action Indicated (OAI) instances dropping by 50% in the last decade and European Medicines Agency (EMA) non-compliance cases falling by 27%.

The Netherlands, being part of the EU, recognizes these regulatory approvals, facilitating the acceptance of Indian Amlodipine formulations. Indian manufacturers have a strong track record of supply reliability, with exports growing at 9%, nearly twice the global average.

India's pharmaceutical industry has demonstrated robust supply reliability, with exports growing at 9% as of February 2025, nearly double the global average. The country has over 650 U.S. FDA-approved manufacturing facilities, ensuring adherence to international quality standards.

Indian manufacturers have invested in advanced packaging and cold chain logistics to maintain the integrity of Amlodipine formulations during transit. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Leading manufacturers continue to expand their capacities to meet growing global demand.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amlodipine formulations.

• Understand Minimum Order Quantities (MOQs): Indian suppliers may have varying MOQs; it's essential to negotiate terms that align with your procurement needs.

• Establish Favorable Payment Terms: Common payment terms in India-Netherlands pharmaceutical trade include letters of credit and advance payments. Negotiate terms that balance cash flow considerations with supplier requirements.

• Conduct Thorough Supplier Qualification: Assess potential suppliers' regulatory compliance, manufacturing capabilities, and quality control measures. On-site audits and reviewing regulatory certifications are recommended.

• Monitor Regulatory Changes: Stay informed about regulatory updates in both India and the Netherlands to ensure ongoing compliance and smooth importation processes.

By adhering to these guidelines, Netherlands companies can establish reliable partnerships with Indian Amlodipine manufacturers, ensuring the delivery of high-quality pharmaceutical formulations to the European market.